Peer review of Pfizer COVID-19 vaccine data confirms 100% effectiveness in adolescents
A new study published in the New England Journal of Medicine is confirming Pfizer’s claims of the high levels of effectiveness among adolescents of its COVID-19 vaccine. The study, which looked at 2,260 adolescents between the ages of 12 and 15, observed 100% efficacy in the group, with a favorable safety and side-effect profile. The authors conclude that the Pfizer vaccine produces a greater immune response for adolescents than it does in young adults.
Related News Articles
Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…
Headline
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to…
Headline
The Centers for Disease Control and Prevention is reminding clinicians and other health care workers to take necessary steps to keep themselves and their…
Chairperson's File
Autumn is here, and that means cooler weather and also the start of flu season.We know the best way to prevent influenza is to get a flu vaccine. The Centers…
Headline
The National Foundation for Infectious Diseases Sept. 25 released a survey showing that less than one in five U.S. adults are concerned about themselves or a…
Headline
The Food and Drug Administration Aug. 22 granted emergency use authorization for two new combined COVID-19 and influenza tests. The Nano-Check Influenza-COVID-…